Curis Inc. (CRIS, Financial), a biotech company specializing in innovative oncology therapies, witnessed a significant stock drop of 5.13%. The stock is currently priced at $4.25 per share, with a trading volume of 37,732 shares and a turnover rate of 0.63%. It experienced a volatility of 10.04%.
Recent financial reports reveal that Curis generated $2.55 million in revenue but reported a net loss of $11.80 million, resulting in an earnings per share of -$2.03. The company's gross profit stands at $2.47 million, and the price-to-earnings ratio is -0.53. Notably, there are no institutional buy, hold, or sell recommendations for this stock currently.
Within the biotechnology industry, where Curis operates, the overall sector experienced a decline of 3.48%. However, some stocks like Ocean Biomedical Inc, Promis Neurosciences Inc., and Mimedx Group, Inc. posted significant gains. Other stocks like Aditxt, Inc., Evogene Ltd., and Gri Bio, Inc. exhibited high activity levels, with turnover rates of 265.90%, 239.77%, and 189.37% respectively. Stocks with notable volatility include Vaccinex, Inc., 180 Life Sciences Corp, and Gri Bio, Inc., reporting amplitudes of 47.15%, 46.15%, and 45.95%.
Curis focuses on developing and commercializing innovative drugs and treatments in the field of immuno-oncology and precision oncology, targeting solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, and hematological cancers. Their product pipeline includes CUDC-907, CA-170, CA-4948, CA-327, and Erivedge.
